|

Toripalimab (anti-PD-1 antibody) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Second Affiliated Hospital, School of Medicine, Zhejiang University1

Indications

  • TNBC - Triple-Negative Breast Cancer1
  • Breast Cancer1
  • Cancer1

Other1 trial

Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.